cyclophosphamide in the treatment of thickening and tightening of ski
Not Applicable
- Conditions
- Health Condition 1: L98- Other disorders of skin and subcutaneous tissue, not elsewhere classifiedHealth Condition 2: null- patient admitted with sclerodactyly,difficulty in opening mouth ,dysphagia
- Registration Number
- CTRI/2015/01/005442
- Lead Sponsor
- Government medical college
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 20
Inclusion Criteria
All patients of systemic sclerosis, satisfying the ACR criteria for systemic sclerosis attending the Out Patient, Department of Dermatology in Calicut Medical College.
Exclusion Criteria
1.Patients who have not given the consent to be a part of the study
2.Pregnant females
3.Patients with major organ involvement
4.Those with previous history of use of cyclophosphamide, prednisolone or other immunosuppressive agents
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Primary outcome is to analyse the effect of low dose intravenous cyclophosphamide on skin sclerosis as assessed by modified Rodnan skin score at 2 months, 4 months of starting treatment and the end of treatment. Further follow up of these patients will be done by revaluations 6 months and one year after the completion of treatment.Timepoint: 2 months, 4 months ,6 months 12 months,18 months
- Secondary Outcome Measures
Name Time Method To assess side effects of cyclophosphamide pulse therapyTimepoint: 6 months,12 months,18 months